ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Health policy"

  • Abstract Number: 1049 • ACR Convergence 2024

    Very Low Uptake of Biosimilar Adalimumab in the First 9 Months of Availability in Rheumatology

    Eric Roberts1, Gabriela Schmajuk2 and Jinoos Yazdany3, 1University of California, San Francisco, SF, CA, 2UCSF / SFVA, San Francisco, CA, 3UCSF, San Francisco, CA

    Background/Purpose: In 2021, over 300,000 patients in the United States used adalimumab, making it one of the highest-grossing drugs globally. In 2023, patent exclusivity for…
  • Abstract Number: 1050 • ACR Convergence 2024

    The Cost-effectiveness of Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs) for Patients with Knee Osteoarthritis and Obesity

    Daniel Betensky1, Jeffrey Katz1, Catherine Yang2, David Hunter3, Jamie Collins1, Candace Feldman1, Karen Smith1, Stephen Messier4, Jason Kim5, Faith Selzer6 and Elena Losina1, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Brookline, MA, 3Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, 4Wake Forest University, Winston Salem, NC, 5Arthritis Foundation, Atlanta, GA, 6Brigham and Women's Hospital, Amesbury, MA

    Background/Purpose: Weight-loss has been shown to alleviate knee osteoarthritis (OA) symptoms in persons with OA and obesity. Utilization of GLP1RA medications has increased rapidly. These…
  • Abstract Number: 1880 • ACR Convergence 2024

    Statewide Burden of Osteoarthritis in India and Its Trend from 1990-2021: A Benchmarking Analysis

    Rafael Sanchez-Dopazo,1, malay rathod2, Ashwinikumar Shandilya3, Janmay Vala4, Eva Kalra5, Tapan Giri6, Saif Syed7, Mohit Lakkimsetti8, Juhi Patel9, VISHRANT AMIN10 and Hardik Desai11, 1Larkin Community Hospital Palm Springs Campus, Hialeah, FL, 2Monmouth Medical Center, Rutgers University, Ewing, NJ, 3Rural Medical college. Pravara institute of medical sciences., Ahmednagar, India, 4Terna Medical College, Navi Mumbai, Maharashtra, India, 5Trident Medical Cente, Charleston, SC, 6BJ Medical College, Pune, Pune, Maharashtra, India, 7Royal college of Surgeons,Dublin,Ireland, Dublin, Dublin, Ireland, 8Mamata Medical College,Khammam, Khammam, Telangana, India, 9GMERS MEDICAL COLLEGE VALSAD, 382330, Gujarat, India, 10GMERS MEDICAL COLLEGE VALSAD, Ahmedabad, India, 11Gujarat Adani Institute of Medical Sciences, Bhuj, India

    Background/Purpose: Osteoarthritis (OA) imposes a significant health burden globally, with India experiencing substantial demographic and epidemiological changes over the past three decades. This study addresses…
  • Abstract Number: 1882 • ACR Convergence 2024

    30-Day Readmission Among Patients with Rheumatoid Arthritis and Their Independent Predictors: Insights from National Readmission Database

    Shobhit Piplani1, Priyanshu Jain2, Vladimir Jelic3, Clement Tagoe4 and Beverly Johnson5, 1Jacobi Medical Center/North Central Bronx Albert Einstein College of Medicine NYC Health and Hospitals, Bronx, NY, 2Jawaharlal Nehru Medical College, Belgaum, Karnataka, India, Bronx, NY, 3Jacobi Medical Center/North Central Bronx, Bronx, NY, 4Albert Einstein College of Medicine, FRESH MEADOWS, NY, 5Albert Einstein College of Medicine, New York, NY

    Background/Purpose: Rheumatoid Arthirits (RA) is associated with heightened morbidity, diminished quality of life, and increased healthcare expenses. This research aims to bridge this gap by…
  • Abstract Number: 1913 • ACR Convergence 2024

    Health Literacy and Disease, Clinical, Functional and Management Outcomes in Inflammatory Arthritis: A Systematic Literature Review

    Mrinalini Dey1, Shyam Budhathoki2, Sofia Ramiro3, Kaleb Michaud4, Helen Elwell5, Sam Norton6, Maya H. Buch7, Andrew Cope1, Richard Osborne8, James Galloway9 and Elena Nikiphorou1, 1King's College London, London, United Kingdom, 2Imperial College London, London, United Kingdom, 3Leiden University Medical Center, Bunde, Netherlands, 4University of Nebraska Medical Center, Omaha, NE, 5British Medical Association, London, United Kingdom, 6King's College London, London, England, United Kingdom, 7Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, 8Swinburne University of Technology, Swinburne, Australia, 9Centre for Rheumatic Diseases, King's College London, London, United Kingdom

    Background/Purpose: Health literacy (HL) is a key social determinant of health in inflammatory arthritis (IA), including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, as it…
  • Abstract Number: 2158 • ACR Convergence 2024

    An MVPA Is MVPA Is MVPA, or Is It? Impact of the Definition of Moderate to Vigorous Physical Activity (MVPA) on Its Amount in Persons with Advanced Knee Osteoarthritis

    Samantha Chin1, Jamie Collins1, Jeffrey Katz2, Dorothy Dunlop3, Lauren Mitchell1, Rowland Chang4, Khara James1, Christine Pellegrini5, Jason Kim6, Katharine Fox1, Anne Holleman1 and Elena Losina1, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Brookline, MA, 3Northwestern University, New Haven, CT, 4Northwestern University Division of Rheumatology, Chicago, IL, 5University of South Carolina, Columbia, SC, 6Arthritis Foundation, Atlanta, GA

    Background/Purpose: ActiGraph is a gold standard for MVPA assessment with several counts per minute (CPM) validated thresholds proposed to measure MVPA. Historically, these thresholds have…
  • Abstract Number: 2587 • ACR Convergence 2024

    A Proprietary AI Rule Engine Assisted by an OpenAI-based ML Model Can Speed up and Better Inform the Prior Authorization Process for Rheumatology Investigations and Medications

    Tanishka Agrawal1, Sumanth Raman2, J. Arun3 and HUMEIRA BADSHA4, 1Dubai International Academy, Dubai, Dubai, United Arab Emirates, 2Algorithm Health, Dubai, Dubai, United Arab Emirates, 3Algorithm Health, Dubai, United Arab Emirates, 4HBMC, Dubai, United Arab Emirates

    Background/Purpose: Patients with chronic autoimmune conditions often need expensive treatments which require prior authorizations by insurance companies. However, significant delays in these processes leave patients…
  • Abstract Number: 2610 • ACR Convergence 2024

    Treatment Concordance of Asynchronous Virtual Visits Compared to Traditional In-person Visits in Patients with Rheumatoid Arthritis: Results of the Prospective, Multi-center, Randomized Controlled TELERA Trial

    Johannes Knitza1, Johanna Mucke2, Manuel Grahammer3, Sebastian Kuhn1, Nicolas Vuillerme4, Felix Muehlensiepen5, Gerhard Krönke6, Georg Schett7, Ann-Christin Pecher8 and Martin Krusche9, and the TELERA Study Group, 1Institute for Digital Medicine, University Hospital Marburg, Philipps-University Marburg, Marburg, Germany, Marburg, Germany, 2Heinrich-Heine-University, Duesseldorf, Germany, 3ABATON, Berlin, Germany, 4AGEIS, Université Grenoble Alpes, 38000 Grenoble, France, Grenoble, France, 5Center for Health Services Research, Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Rüdersdorf, Germany, Berlin, Germany, 6Rheumatology, Charité, Berlin, Germany, 7Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 8Interdisciplinary Center of Rheumatic Diseases (INDIRA), University Hospital Tuebingen, Tuebingen, Germany, Tübingen, Germany, 9III Department of Medicine, Division of Rheumatology and Systemic Inflammatory Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Hamburg, Germany

    Background/Purpose: Access to rheumatology care is becoming increasingly limited, necessitating a re-evaluation of patient pathways. The objective of this study was to evaluate a new…
  • Abstract Number: 0161 • ACR Convergence 2024

    Cross Country Burden of Osteoarthritis in Latin America and Caribbean from 1990-2021: A Comparative and Consistent Benchmarking Analysis for the Global Burden of Disease Study 2022

    malay rathod1, Eva Kalra2, Rafael Sanchez-Dopazo,3, Janmay Vala4, Saif Syed5, Akhilesh Sharma6, Ashwinikumar Shandilya7, Asmita Gera8, Mohit Lakkimsetti9, Juhi Patel10, VISHRANT AMIN11 and Hardik Desai12, 1Monmouth Medical Center, Rutgers University, Ewing, NJ, 2Trident Medical Cente, Charleston, SC, 3Larkin Community Hospital Palm Springs Campus, Hialeah, FL, 4Terna Medical College, Navi Mumbai, Maharashtra, India, 5Royal college of Surgeons,Dublin,Ireland, Dublin, Dublin, Ireland, 6Adesh Institute of Medical Sciences and Research, Bhatinda, India, 7Rural Medical college. Pravara institute of medical sciences., Ahmednagar, India, 8Tianjin medical University, Tianjin, China, Tianjin, Tianjin, China (People's Republic), 9Mamata Medical College,Khammam, Khammam, Telangana, India, 10GMERS MEDICAL COLLEGE VALSAD, 382330, Gujarat, India, 11GMERS MEDICAL COLLEGE VALSAD, Ahmedabad, India, 12Gujarat Adani Institute of Medical Sciences, Bhuj, India

    Background/Purpose: Osteoarthritis (OA) poses a significant and escalating health challenge across Latin America and the Caribbean (LAC), driven by demographic shifts, lifestyle factors, and varying…
  • Abstract Number: 0353 • ACR Convergence 2024

    Identifying Solutions to Address Racial and Ethnic Health Disparities in Lupus: A Consensus-Based Approach

    Joy Buie1, Michael Fisher1, Hannah Tlydsley2, Kristen Backor2 and Karen Costenbader3, 1Lupus Foundation of America, Washington, DC, 2Charles River Associates, San Francisco, CA, 3Brigham and Women's Hospital/ Harvard Medical School, Boston, MA

    Background/Purpose: Health disparities among racial and ethnic minoritized individuals living with lupus remain a critical public health concern. Challenges related to healthcare affordability, accessibility, and…
  • Abstract Number: 1046 • ACR Convergence 2024

    Shifting Paradigms in Drug Spending: A Study of Medicare Part D versus Emerging Pharmacy Models in Rheumatology

    Katherine Schoeffler, Stephanie Beveridge, Max Bouvette, Veera Durga Vaishnavi Kurra, Reema Moussa, Ryan Johnson, Camille Goerend, Nimrah Bader and Ryan Nipp, University of Oklahoma College of Medicine, Oklahoma City, OK

    Background/Purpose: Recent policy changes and competitive alternative drug pricing models present the potential for medication cost savings. In this study, we sought to assess the…
  • Abstract Number: 0159 • ACR Convergence 2023

    Understanding the Economic Impact of Autoimmune Eye Disease in the United States

    Krati Chauhan1, Steven Scaife2 and Michael Buhnerkempe1, 1Southern Illinois University - School of Medicine, Springfield, IL, 2Southen Illinois University - School of Medicine., Springfield, IL

    Background/Purpose: Eye involvement is an important cause of morbidity in rheumatology patients. Inflammatory eye diseases include conditions like scleritis, uveitis, retinitis and orbital inflammation. The…
  • Abstract Number: 0161 • ACR Convergence 2023

    Differences and Similarities Between the EULAR/ASAS-EULAR Recommendations and National Recommendations for Treatment of Patients with Psoriatic Arthritis and Axial Spondyloarthritis Across Europe

    Brigitte Michelsen1, Mikkel Østergaard2, Michael Nissen3, Adrian Ciurea4, Burkhard Moeller5, Lykke Ørnbjerg6, Jakub Zavada7, Bente Glintborg8, Alan MacDonald9, Karin Laas10, Dan Nordstrom11, Bjorn Gudbjornsson12, Florenzo Iannone13, Pasoon Hellamand14, Tore Kvien15, Ana Maria Rodrigues16, Catalin Codreanu17, Ziga Rotar18, Isabel Castrejon19, Johan Karlsson Wallman20, Jiri Vencovsky21, Anne Gitte Loft22, Maureen Heddle23, Sigrid Vorobjov24, Anna-Mari Hokkanen25, Gerdur Maria Grondal26, Marco Sebastiani27, Marleen van de Sande28, Eirik Kristianslund29, Maria Jose Santos30, Corina Mogosan31, Matija Tomsic32, Jose Federico Diaz-Gonzalez33, Daniela Di Giuseppe34 and Merete Hetland6, 1Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, 2Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, 3Geneva University Hospitals, Geneva, Switzerland, 4University Hospital Zurich, Zürich, Switzerland, 5Inselspital - University Hospital Bern, Bern, Switzerland, 6Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, 7Institute of Rheumatology; Charles University, Prague, Czech Republic, 8Rigshospitalet Glostrup, University of Copenhagen, Virum, Denmark, 9NHS Grampian, Aberdeen, United Kingdom, 10Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia, 11Helsinki University Hospital, Helsinki, Finland, 12Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, 13Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, 14Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, 15Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 16Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, 17Center for Rheumatic Diseases, Bucharest, Romania, 18University Medical Centre Ljubljana, Ljubljana, Slovenia, 19Hospital General Universitario Gregorio Marañón, Madrid, Spain, 20Lund University and Skåne University Hospital, Lund, Sweden, 21Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 22Aarhus University, Horsens, Denmark, 23Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, United Kingdom, 24National Institute for Health Development, Tallinn, Estonia, 25Helsinki University and Helsinki University Hospital, Helsinki, Finland, 26Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, 27Azienda Policlinico di Modena, Modena, Italy, 28Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, 29Diakonhjemmet Hospital, Oslo, Norway, 30Hospital Garcia de Orta, Almada, Lisboa, Portugal, 31University of Medicine and Pharmacy, Bucharest, Romania, 32University Medical Centre Ljubljana; Universitiy of Ljubljana, Ljubliana, Slovenia, 33Hospital Universitario de Canarias, La Laguna, Spain, 34Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: National treatment recommendations are often used to optimize patient care and may differ from international recommendations. The aim of this study was to assess…
  • Abstract Number: 0175 • ACR Convergence 2023

    Predicting Cost-Related Medication Non-Adherence in US Adults with Chronic Arthritis: A Machine Learning Approach

    Ashkan Ara1, Matthew Chenoweth1 and Christopher Scannell2, 1University of California Los Angeles, Los Angeles, CA, 2UCLA / West Los Angeles VA Medical Center, Los Angeles, CA

    Background/Purpose: Cost-related medication non-adherence (CRN) occurs when patients are unable to follow their prescribed medication regimen due to financial constraints, such as high costs or…
  • Abstract Number: 0177 • ACR Convergence 2023

    Cost-Related Medication Non-Adherence Among US Adults with Chronic Arthritis: Trends, Comparisons, and Disparities

    Ashkan Ara1, Matthew Chenoweth1, Christopher Scannell2 and John FitzGerald1, 1University of California Los Angeles, Los Angeles, CA, 2UCLA / West Los Angeles VA Medical Center, Los Angeles, CA

    Background/Purpose: Cost-related medication non-adherence (CRN), a measure of drug affordability, refers to a patient's inability to adhere to a prescribed medication regimen due to high…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology